Scholarlink

<p>Favipiravir is an anti-influenza prodrug that is metabolized to its phosphoribosylated form, favipiravir-ribofuranosyl-5′-monophosphate (favipiravir-RMP), by human endogenous enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). This enzymatic reaction is the rate-determining step in generating the active form of favipiravir, making it important to understand the molecular mechanisms underlying the HGPRT-catalyzed RMP-modification of favipiravir. However, the pharmacokinetics of this reaction have not been fully elucidated, despite X-ray crystallographic studies on the HGPRT-favipiravir complex. Here, we identified functional hot-spot residues in HGPRT that play important roles in the enzymatic conversion of favipiravir to favipiravir-RMP. Real-time monitoring of the HGPRT reaction via ligand-observed solution NMR experiments, biochemical mutagenesis of HGPRT, and computational calculations and molecular dynamics simulations, allowed us to investigate the free binding energetics and structural properties of the interaction between HGPRT and favipiravir-RMP. This powerful hybrid experimental strategy allows the identification of functional hot-spot residues in the enzyme and provide complementary structural biological information. This approach could be universally applicable to investigating drug-protein interaction modes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Investigation of the functional hot-spot residues of an enzyme by real-time monitoring of the enzymatic reaction using NMR and computational approaches

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月13日

查看全文
  • Toshihiko Sugiki,
  • Tomoki Yoshida,
  • Masaki Tsukamoto,
  • Koichiro Miyanishi,
  • Akinori Kagawa,
  • Natsuko Miura,
  • Tomoto Ura,
  • Jun Fukazawa,
  • Yuko Hatanaka,
  • Tsuyoshi Murata,
  • Toshimichi Fujiwara,
  • Masahiro Kitagawa,
  • Yasushi Morita,
  • Kumiko Sakai-Kato,
  • Yoichi Takakusagi,
  • Nobutada Tanaka,
  • Makoto Negoro

摘要

Favipiravir is an anti-influenza prodrug that is metabolized to its phosphoribosylated form, favipiravir-ribofuranosyl-5′-monophosphate (favipiravir-RMP), by human endogenous enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). This enzymatic reaction is the rate-determining step in generating the active form of favipiravir, making it important to understand the molecular mechanisms underlying the HGPRT-catalyzed RMP-modification of favipiravir. However, the pharmacokinetics of this reaction have not been fully elucidated, despite X-ray crystallographic studies on the HGPRT-favipiravir complex. Here, we identified functional hot-spot residues in HGPRT that play important roles in the enzymatic conversion of favipiravir to favipiravir-RMP. Real-time monitoring of the HGPRT reaction via ligand-observed solution NMR experiments, biochemical mutagenesis of HGPRT, and computational calculations and molecular dynamics simulations, allowed us to investigate the free binding energetics and structural properties of the interaction between HGPRT and favipiravir-RMP. This powerful hybrid experimental strategy allows the identification of functional hot-spot residues in the enzyme and provide complementary structural biological information. This approach could be universally applicable to investigating drug-protein interaction modes.